Teva Pharma (TEVA) Rating Restated
Teva Pharma (TEVA) had its stock rating noted as “Underperform” by analysts at Leerink Partners. Leerink Partners currently has a $17.0 target price per share on the $ market cap company or -19.66 % downside potential. This was revealed in an analyst report on Friday morning.
TEVA is right now trading 0.00% lower at $0.00 as of 8:05 AM New York time. Teva Pharma’s stock is 0% in the last 200 days. It has underperformed the S&P500, which has gained 6.00% in the same time period.
Out of 22 analysts covering Teva Pharma, 19 rate it a Buy, 6 indicate a Hold while 0 suggest a Sell. The highest target is $100 and the lowest is $58 according to Thomson/First Call. The 12-month mean target is $72.82, which means upside potential of ∞% over the current price.
Teva Pharma (TEVA) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Teva Pharma has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Teva Pharma (TEVA) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Teva Pharma (TEVA) “Underperform” Rating Reiterated by Leerink Partners; The Target is $17.0 appeared first on Octafinance.